UPDATE 1-U.S. panel backs approval of Sanofi combination diabetes drug

May 25, 2016 8:59 PM

20 0

May 25 One day after recommending approval of a new diabetes drug made by Novo Nordisk A/S, a U.S. advisory panel on Wednesday recommended approval of a similar product made by Sanofi SA.

The panel voted 12-2, with one person not voting, that the Food and Drug Administration should approve Sanofi's combination drug, iGlarLixi, for patients with type 2 diabetes. The agency is not obliged to follow the advice of its advisory panels but typically does so.

Read more

To category page